Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E7.04 EPS (ttm)11.69 Insider Own0.50% Shs Outstand1.33B Perf Week-0.22%
Market Cap109.57B Forward P/E6.67 EPS next Y12.33 Insider Trans-14.98% Shs Float1.32B Perf Month-4.97%
Income17.34B PEG10.91 EPS next Q2.99 Inst Own81.90% Short Float1.87% Perf Quarter-9.94%
Sales32.84B P/S3.34 EPS this Y62.00% Inst Trans-5.91% Short Ratio2.51 Perf Half Y-19.57%
Book/sh9.69 P/B8.49 EPS next Y2.24% ROA36.60% Target Price110.89 Perf Year-28.41%
Cash/sh6.25 P/C13.17 EPS next 5Y0.65% ROE105.70% 52W Range77.92 - 118.14 Perf YTD-17.85%
Dividend1.88 P/FCF6.89 EPS past 5Y48.30% ROI45.90% 52W High-29.55% Beta1.12
Dividend %2.29% Quick Ratio1.60 Sales past 5Y32.60% Gross Margin86.90% 52W Low6.81% ATR1.88
Employees8000 Current Ratio1.80 Sales Q/Q2.60% Oper. Margin65.40% RSI (14)48.77 Volatility2.58% 1.94%
OptionableYes Debt/Eq1.70 EPS Q/Q-8.60% Profit Margin52.80% Rel Volume0.70 Prev Close82.27
ShortableYes LT Debt/Eq1.57 EarningsJul 26 AMC Payout14.30% Avg Volume9.83M Price83.23
Recom2.10 SMA20-0.47% SMA50-3.65% SMA200-11.56% Volume5,854,051 Change1.17%
Jun-01-16Initiated Gabelli & Co Buy $109
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Feb-12-16Reiterated Maxim Group Buy $137 → $115
Feb-03-16Reiterated RBC Capital Mkts Outperform $130 → $120
Feb-03-16Reiterated Piper Jaffray Overweight $134 → $114
Feb-03-16Reiterated Oppenheimer Outperform $124 → $120
Feb-03-16Reiterated Barclays Overweight $130 → $115
Feb-03-16Initiated Standpoint Research Buy $110
Jan-20-16Initiated Credit Suisse Outperform $125
Jan-15-16Upgrade BofA/Merrill Underperform → Neutral $107
Oct-28-15Reiterated Maxim Group Buy $129 → $137
Oct-20-15Reiterated Oppenheimer Outperform $120 → $124
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-09-15Initiated Jefferies Hold
Jul-29-15Reiterated RBC Capital Mkts Outperform $120 → $130
Jul-29-15Reiterated Piper Jaffray Overweight $131 → $134
Jul-29-15Reiterated Oppenheimer Outperform $86 → $120
Jun-29-16 06:40PM  This Biotechs Stock Just Doubled and Its Bad News for Sanofi at Fortune
04:44PM  The First-Ever Drug to Treat All Major Hep C Strains Just Got Approved at Fortune
03:44PM  3 Biotech Stocks to Buy on Sale Right Now at Motley Fool
02:35PM  Top 6 Research Reports for June 29, 2016
02:23PM  Biotech Stock Roundup: Gilead Gets FDA Nod for HCV Drug, Regulus Hit by Clinical Hold
01:31PM  Gilead Reverses Price Course at Bloomberg
10:23AM  How Much Will the Elections Affect Healthcare Stocks? at Motley Fool
10:19AM  Gilead Sciences: Still the Most Undervalued Stock in Biotech at Barrons.com
08:54AM  Gilead's hepatitis C drug wins FDA approval
Jun-28-16 07:38PM  Gilead's Hepatitis C Drug Approved by FDA +5.19%
07:37PM  Gilead's Hepatitis C Drug Approved by FDA at Bloomberg
06:40PM  The FDA Unsurprisingly Approves Gilead's New Hepatitis C Drug. Now What? at Motley Fool
06:00PM  Life or Death: Why Chinese Patients Mix Drug Cocktails at Home at Bloomberg
05:58PM  Final Trade: GILD, OLED, PYPL & NKE
04:59PM  Gilead Hepatitis C Pill Approved For Broad Use, Priced Below Sovaldi
04:19PM  FDA approves first pill to treat all forms of hepatitis C
03:59PM  FDA approves first pill to treat all forms of hepatitis C at San Jose Mercury News
03:50PM  Why Gilead's new hepatitis C drug is a game changer price and all at bizjournals.com
03:20PM  Gilead Hepatitis C Pill Approved For Broad Use, Priced Below Sovaldi
02:46PM  Why Gilead (GILD) Stock Is Gaining Today
02:40PM  Gilead wins U.S. nod for drug for all types of hepatitis C Reuters
02:34PM  Instant Analysis: Gilead Sciences Wins an Important FDA Approval at Motley Fool
02:28PM  Gilead Sciences: Dominating at Barrons.com
01:43PM  Gilead receives approval for cheaper hepatitis C drug at MarketWatch
01:14PM  Gilead gets approval for hep C drug
12:59PM  Why Is Gilead Sciences (GILD) Stock Gaining Today?
12:32PM  Gilead Gets FDA Approval for Combo Hepatitis C Drug at The Wall Street Journal
12:01PM  5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero at 24/7 Wall St.
12:01PM  This Leading Indicator Suggests the Stock Market May Be on the Precipice of Tumbling at Motley Fool
11:41AM  FDA approves first pill to treat all forms of hepatitis C at Los Angeles Times
11:40AM  Gilead Gets FDA Approval For Epclusa (Sofosbuvir/Velpatasvir) for All Genotypes Of Chronic Hepatitis C Treatment
11:35AM  Gilead Sciences Bucks Tradition, Takes 'Low Road' on New Hepatitis C Drug Price
11:31AM  A drug that can treat all strains of hepatitis C just got approved
11:07AM  Inside AbbVies Analyst Recommendations in 2016
10:55AM  Biotechs: After Brexit, Buy the Stocks and Get the Pipelines For Free at Barrons.com
10:46AM  U.S. FDA approves Gilead's hep C drug Epclusa Reuters
10:25AM  U.S. Food and Drug Administration Approves Gileads Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C Business Wire
08:00AM  Hunting for health-care winners
Jun-27-16 11:45PM  Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied? at Motley Fool
09:42PM  The Largest Drug Pipelines Will Surprise You
03:43PM  When Will Gilead Sciences, Celgene, and CVS Health Hit $100 Again? at Motley Fool
10:29AM  Is Brexit Good for Biotech? Maybe at Barrons.com
09:30AM  Gilead's Slow Road Is the Right Road at Bloomberg
07:55AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
Jun-25-16 02:01PM  3 Biotech Stocks to Buy Now for the Long Haul at Motley Fool
12:05PM  Can Gilead Sciences Rebound in the Second Half of 2016? at Motley Fool
12:20AM  [$$] Biotech Labs Birth New Drugsand New Fortunes at The Wall Street Journal
12:01AM  [$$] U.S. Cheese Prices Fall at Barrons.com
Jun-24-16 04:56PM  2 Key FDA Actions On Potential Blockbuster Drugs Next Week
04:34PM  How Does Brexit Affect Biotech Stocks? Wall Street Weighs In
02:41PM  2 Biotech Stocks That Won't Pay a Dividend Anytime Soon, and 1 That Should at Motley Fool
01:53PM  Biotech: Buy the Brexit Blowup? at Barrons.com
10:08AM  Gilead's (GILD) HIV Treatment Odefsey Gains Approval in EU
Jun-23-16 06:56PM  The Largest and Most Absurd Stock Buybacks
12:55PM  Big Biotech Set to Bounce Off Deep Lows (GILD, CELG) at Investopedia
12:32PM  Heres Why CVD Equipment, Micron and Three Other Stocks Are in Spotlight Today at Insider Monkey
11:49AM  Gilead Sciences: What's Next in Hepatitis C? at Barrons.com
11:30AM  Gilead Sciences Get European Commission Grant For Marketing Authorization Of Its Single Tablet Regimen Odefsey
10:41AM  The 3 Most Important Data Releases and FDA Decisions in the Second Half of 2016 at Motley Fool
08:48AM  As Buybacks Soar, Buyback ETF Tries To Get Its Groove Back
08:05AM  20 Companies Buying Back the Most Stock in 2016 at 24/7 Wall St.
07:53AM  European Commission Grants Marketing Authorization for Gileads Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV Business Wire
Jun-22-16 05:04PM  Gilead, Apple Lead Stock Buybacks, Which Hit 9-Year High In Q1
03:03PM  Gilead Downside Is Path of Least Resistance
02:58PM  U.S. companies spent record amount on buybacks over past 12 months at MarketWatch
02:08PM  Hepatitis B Virus (HBV) Therapeutics Report 2016 - 5EU Drug Forecast and Market Analysis to 2024 - Research and Markets Business Wire
12:51PM  Stocks Erased Gains; Biotechs, KB Home Jump As Tesla Dives
12:22PM  Medicare 'Death Panel' Is On Ice; Biotech Stocks Heat Up
10:50AM  Biotech: Why Take the Risk? at Barrons.com
10:30AM  The Top 20 Most Generous Companies Gave $3.5 Billion to Charity Last Year at Fortune
08:21AM  Can These Upstarts Knock Gilead Sciences Off Its Perch? at Motley Fool
Jun-21-16 11:21AM  Gilead Presents Favorable Preliminary Bictegravir HIV Data
09:53AM  New Strong Sell Stocks for June 21st
09:38AM  Gilead Sciences: The Perfect Cocktail? at Barrons.com
08:03AM  These 5 Biotech Stocks Are Ridiculously Cheap at Motley Fool
Jun-20-16 06:34PM  A new way to cut drug prices? Make Big Pharma show what it spends to bring drugs to market at Los Angeles Times
06:04PM  Why Achillion Pharmaceuticals Is Down Big in 2016 at Motley Fool
12:25PM  Gilead Sciences Bounces on Preliminary Results at 24/7 Wall St.
08:57AM  Biotech stocks are in for more election trouble on drug pricing at MarketWatch
08:36AM  A Market-Based Proposal For Controlling Drug Prices at Forbes
08:30AM  Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV Business Wire
Jun-19-16 03:03PM  Gilead Sciences: Where's the Value? at Motley Fool
02:02PM  The 3 Best Dividend Stocks for Beginning Investors at Motley Fool
Jun-18-16 09:41AM  2 Biotech Stocks That Could Raise Their Dividends -- and 1 That Won't at Motley Fool
Jun-17-16 03:40PM  3 Reasons Gilead Sciences Is a Buy at Motley Fool
10:25AM  Gilead Sciences: A 'Strong Uptick' in New Hepatitis C Prescriptions at Barrons.com
07:51AM  Are You Ready to Buy Gilead?
Jun-15-16 01:05PM  Gilead Sciences: You Want Revenue? We Got Your Revenue at Barrons.com
Jun-14-16 04:20PM  3 Biotech Stocks to Buy If the Market Crashes at Motley Fool
03:32PM  Biotech: Still Troubled at Barrons.com
10:22AM  Gilead Stock Trades Ex-Dividend Tuesday (GILD) at Investopedia
10:11AM  Why Infinity Pharmaceuticals (INFI) Stock Is Tanking Today
Jun-13-16 05:00PM  Gilead Sciences to Present at the 36th Annual William Blair Growth Stock Conference on Tuesday, June 14 Business Wire
10:08AM  Gilead Stock Falls on Weak Hepatitis-C Prospects (GILD) at Investopedia
Jun-12-16 05:25PM  Insiders See Huge Upside In These Biotechs
02:35PM  Biogen And Gilead Sciences Buck Biotech Short Interest Trend
07:20AM  Dividend Stocks Retirees Can Buy at Motley Fool
Jun-11-16 12:01PM  My Favorite Clinical-Stage Biotech Stocks to Buy at Motley Fool
06:42AM  3 Stocks That Are Ridiculously Cheap Right Now at Motley Fool
Jun-10-16 02:32PM  Gilead (GILD) Stock Down, Leerink Expects Further Hepatitis-C Sales Erosion
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company's products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MILLIGAN JOHN FPresident and CEOJun 06Option Exercise16.40112,0001,836,2401,170,963Jun 08 06:59 PM
MILLIGAN JOHN FPresident and CEOJun 06Sale86.94112,0009,736,7791,058,963Jun 08 06:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise24.912,00049,81063,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise16.40100,0001,639,5004,119,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale87.022,000174,04061,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale86.72100,0008,671,9504,019,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Option Exercise33.8857,0921,934,021118,214Jun 02 04:35 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Sale86.8557,0924,958,60061,122Jun 02 04:35 PM
MARTIN JOHN CExecutive ChairmanMay 02Option Exercise16.40100,0001,639,5004,119,727May 04 02:44 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Option Exercise39.132,00078,25563,122May 04 04:23 PM
MILLIGAN JOHN FPresident and CEOMay 02Option Exercise16.40112,0001,836,2401,170,963May 04 02:49 PM
MARTIN JOHN CExecutive ChairmanMay 02Sale87.82100,0008,781,6944,019,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Sale87.71112,0009,823,9541,058,963May 04 02:49 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Sale88.722,000177,44861,122May 04 04:23 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Option Exercise26.9935,874968,239177,964Apr 21 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Sale100.0140,0004,000,574137,964Apr 21 01:28 PM
MILLIGAN JOHN FPresident and CEOApr 04Option Exercise16.40112,0001,836,2401,170,963Apr 05 07:30 PM
MILLIGAN JOHN FPresident and CEOApr 04Sale94.59112,00010,593,9041,058,963Apr 05 07:30 PM
MARTIN JOHN CExecutive ChairmanApr 01Option Exercise16.40100,0001,639,5004,119,727Apr 05 07:49 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise24.912,00049,81063,122Apr 05 06:36 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale91.342,000182,68061,122Apr 05 06:36 PM
MARTIN JOHN CExecutive ChairmanApr 01Sale93.24100,0009,323,5074,019,727Apr 05 07:49 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale91.235,000456,158142,090Apr 05 07:45 PM
Alton Gregg HEVP, Corp & Med AffairsMar 14Sale90.005,000450,000147,090Mar 15 07:31 PM
MARTIN JOHN CChairman and CEOMar 01Option Exercise16.40100,0001,639,5004,119,727Mar 03 02:47 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Option Exercise16.40112,0001,836,2401,170,963Mar 03 02:54 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Option Exercise24.912,00049,81063,122Mar 03 03:10 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Sale87.79112,0009,832,9951,058,963Mar 03 02:54 PM
MARTIN JOHN CChairman and CEOMar 01Sale88.58100,0008,857,8544,019,727Mar 03 02:47 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Sale87.902,000175,80061,122Mar 03 03:10 PM
Washington Robin LEVP, CFOFeb 16Sale90.726,250567,00084,688Feb 18 07:59 PM
MARTIN JOHN CChairman and CEOFeb 01Option Exercise16.40100,0001,639,5004,048,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Option Exercise39.142,00078,27150,783Feb 03 05:42 PM
MARTIN JOHN CChairman and CEOFeb 01Sale83.42100,0008,342,4753,948,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Sale82.322,000164,64048,783Feb 03 05:42 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Option Exercise25.762,00051,52650,783Jan 06 05:08 PM
MARTIN JOHN CChairman and CEOJan 04Option Exercise16.40100,0001,639,5004,048,066Jan 06 05:21 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Sale99.202,000198,40048,783Jan 06 05:08 PM
MARTIN JOHN CChairman and CEOJan 04Sale97.68100,0009,767,7083,948,066Jan 06 05:21 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Option Exercise21.9970,0001,539,562197,936Dec 17 03:40 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Sale102.4170,0007,168,741127,936Dec 17 03:40 PM
MILLIGAN JOHN FPresident and COODec 07Option Exercise14.50100,0001,450,2501,129,108Dec 09 02:14 PM
MILLIGAN JOHN FPresident and COODec 07Sale103.18100,00010,317,9771,029,108Dec 09 02:14 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise14.50150,0002,175,3754,098,066Dec 03 01:57 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.3010,000242,950141,422Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise26.992,00053,98050,783Dec 03 01:56 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale106.0112,0001,272,159129,422Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale106.382,000212,76048,783Dec 03 01:56 PM
MARTIN JOHN CChairman and CEODec 01Sale105.82150,00015,873,4673,948,066Dec 03 01:57 PM
Cogan John FrancisDirectorNov 24Option Exercise20.7115,000310,57559,309Nov 25 02:21 PM
Cogan John FrancisDirectorNov 24Sale105.9515,0001,589,19044,309Nov 25 02:21 PM
Whitley Richard JamesDirectorNov 24Sale106.4816917,99530,719Nov 25 02:22 PM
Whitley Richard JamesDirectorNov 23Sale107.182,863306,84530,888Nov 25 02:22 PM
Whitley Richard JamesDirectorNov 20Sale106.995,514589,91733,751Nov 25 02:22 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Option Exercise23.7670,0001,662,850235,168Nov 18 12:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Sale102.6570,0007,185,419165,168Nov 18 12:32 PM
MILLIGAN JOHN FPresident and COONov 09Option Exercise14.50100,0001,450,2501,129,108Nov 12 01:01 PM
MILLIGAN JOHN FPresident and COONov 09Sale107.66100,00010,765,6441,029,108Nov 12 01:01 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000033,724Nov 09 05:41 PM
MARTIN JOHN CChairman and CEONov 02Option Exercise14.50150,0002,175,3754,098,066Nov 04 01:23 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Option Exercise24.3010,000242,950143,422Nov 04 02:41 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Sale109.3812,0001,312,507131,422Nov 04 02:41 PM
MARTIN JOHN CChairman and CEONov 02Sale109.42150,00016,413,0263,948,066Nov 04 01:23 PM
Carter Paul RutherfordEVP Commercial OpsNov 02Sale108.362,000216,71248,783Nov 04 04:27 PM
Washington Robin LEVP, CFONov 02Sale109.466,250684,15088,046Nov 04 04:21 PM
Cogan John FrancisDirectorOct 27Option Exercise20.7115,000310,57559,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 27Sale110.0015,0001,650,00044,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 26Option Exercise20.7115,000310,57559,309Oct 27 03:09 PM
Cogan John FrancisDirectorOct 26Sale110.0015,0001,650,00044,309Oct 27 03:09 PM
Carter Paul RutherfordEVP Commercial OpsOct 26Sale110.061,500165,09248,783Oct 28 02:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Option Exercise23.6070,0001,652,248235,168Oct 16 05:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Sale100.0570,0007,003,220165,168Oct 16 05:32 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise14.50100,0001,450,2501,129,108Oct 08 02:06 PM
MILLIGAN JOHN FPresident and COOOct 07Sale99.22100,0009,921,5241,029,108Oct 08 02:06 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Option Exercise24.305,000121,475138,422Oct 07 01:22 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Sale100.005,000500,000133,422Oct 07 01:22 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise14.50150,0002,175,3754,098,066Oct 05 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise24.305,000121,475140,422Oct 05 02:13 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale97.287,000680,930133,422Oct 05 02:13 PM
MARTIN JOHN CChairman and CEOOct 01Sale97.48150,00014,622,2893,948,066Oct 05 01:28 PM
Carter Paul RutherfordEVP Commercial OpsOct 01Sale98.592,000197,18048,783Oct 05 04:26 PM
Cogan John FrancisDirectorSep 15Option Exercise20.7115,000310,57559,309Sep 17 03:54 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 15Option Exercise23.6070,0001,652,000235,168Sep 17 04:26 PM
Alton Gregg HEVP, Corp & Med AffairsSep 15Option Exercise24.305,000121,475140,422Sep 17 03:55 PM
Alton Gregg HEVP, Corp & Med AffairsSep 15Sale110.005,000550,000135,422Sep 17 03:55 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 15Sale110.7070,0007,749,195165,168Sep 17 04:26 PM
Cogan John FrancisDirectorSep 15Sale110.0015,0001,650,00044,309Sep 17 03:54 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise14.50100,0001,450,2501,129,108Sep 10 02:57 PM
MILLIGAN JOHN FPresident and COOSep 08Sale103.39100,00010,338,7301,029,108Sep 10 02:57 PM
Washington Robin LEVP, CFOSep 02Sale102.206,250638,77894,296Sep 03 03:07 PM
Alton Gregg HEVP, Corp & Med AffairsSep 01Option Exercise24.2210,000242,208147,422Sep 03 03:06 PM
Alton Gregg HEVP, Corp & Med AffairsSep 01Sale102.7512,0001,233,008135,422Sep 03 03:06 PM
WILSON GAYLE EDirectorAug 28Option Exercise20.7180,0001,656,400122,769Aug 31 06:17 PM
WILSON GAYLE EDirectorAug 28Sale106.9621,0002,246,160101,769Aug 31 06:17 PM
MARTIN JOHN CChairman and CEOAug 25Sale105.17133,21314,009,8720Aug 26 05:51 PM
Alton Gregg HEVP, Corp & Med AffairsAug 03Option Exercise23.7615,000356,325154,422Aug 04 05:08 PM
Cogan John FrancisDirectorAug 03Option Exercise20.7115,000310,57559,309Aug 04 05:01 PM
MARTIN JOHN CChairman and CEOAug 03Option Exercise14.50150,0002,175,3754,364,492Aug 04 05:07 PM
Carter Paul RutherfordEVP Commercial OpsAug 03Option Exercise26.995,000134,95053,783Aug 04 05:08 PM
Carter Paul RutherfordEVP Commercial OpsAug 03Sale119.185,000595,92048,783Aug 04 05:08 PM